Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5)

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

• Tirzepatide is a novel, once-weekly, dual GIP/GLP1 receptor agonist.
• SURPASS-5 aimed to show that tirzepatide 10 mg and 15 mg when added to titrated insulin glargine are superior to placebo in HbA1c change from baseline to Week 40.
• There were robust and clinically meaningful improvements in glycemic control, with up to 97% of tirzepatide patients reaching HbA1c <7.0% at Week 40, compared to 34% of placebo patients.
• Tirzepatide delivered significant reduction in body weight, without increased risk of hypoglycemia.